- Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).
- The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus’ self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
- Also see: Arcturus’ COVID-19 Booster Shows Durability Against Omicron Variants.
- The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
- Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.
New York Cannabis Cops Seized $54M In Illicit Weed From Unlicensed Storefronts, Says Gov. Hochul
New York law enforcement authorities have had a busy year running from one illegal weed shop after another. Gov. Kathy Hochul’s administration announced on Monday that they seized more than 11,000 pounds of illicit cannabis products worth more than $54 million following the latest round of inspections of unlicensed weed-selling storefronts.
